Search

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Read more

Is TRTH for me?

Please see the eligibility criteria in the dropdown menu below.

Read more

Immune Therapies for Hematologic Disorders

Recently the treatment of hematological and solid malignancies has been revolutionized by the introduction of novel immunotherapeutic strategies.

Read more

Hematology Jobs

In this section of the EHA website, job opportunities within the field of hematology are posted, when available. Regulations

Service meant for hematologists and related disciplines.

Read more